daclatasvir

Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

Monodes(N-carboxymethyl)valine Daclatasvir, also known as Daclatasvir Impurity A, is the principal degradation product of Daclatasvir.Daclatasvir is a potent inhibitor of the HCV NS5A protein[1].

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antivirals to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has not been convincingly implicated in cases of clinically apparent liver injury with jaundice.

Daclatasvir Impurity B, a noted impurity of the antiviral agent Daclatasvir, acts as a potent inhibitor of the HCV NS5A protein [1].

Daclatasvir Impurity C is an impurity found in Daclatasvir, a robust inhibitor of the HCV NS5A protein [1].

Daclatasvir-d6 is the deuterated form of Daclatasvir. Daclatasvir (BMS-790052) is a potent orally active inhibitor of the HCV NS5A protein, with an EC50 range of 9-146 pM across various HCV replicon genotypes. Additionally, Daclatasvir acts as an inhibitor of organic anion transporting polypeptides 1B (OATP1B) and OATP1B3, with IC50 values of 1.5 µM and 3.27 µM, respectively.

NS5A-IN-3 (Compound 15) is a potent NS5A inhibitor with high efficacy against HCV genotype 1b, enhanced activity towards genotype 3a (GT 3a), and substantial metabolic stability. It exhibits superior resistance barrier compared to daclatasvir in genotype 1b [1].